Clinical trials: Hyperkalemia
Hyperkalemia, Hemodialysis
Hyperkalaemia Prevalence, Recurrence and Treatment in Haemodialysis
The objective of this study is to evaluate the prevalence and recurrence of Hyperkalaemia (HK) in Chinese HD patients and to understand the treatment pattern of HK in China.
- Conditions
- Hyperkalemia, Hemodialysis, Water-Electrolyte Imbalance
- Trial name
- PRECEDE-K (NCT04799067)
- Testing
- observational study
- Where
- 12 sites in China
- Volunteers
- 600 people
- Sponsor
- AstraZeneca
Hyperkalemia
A Study to Test Whether ZS (Sodium Zirconium Cyclosilicate) Can Reduce the Incidence of Increased Blood Potassium Levels Among Dialized Patients.
The purpose of this study is to evaluate the efficacy of ZS in the treatment of hyperkalemia in patients on hemodialysis.
- Trial name
- DIALIZE (NCT03303521)
- Testing
- Sodium Zirconium Cyclosilicate (ZS)
- Where
- 53 sites in United States, Japan and 2 more
- Volunteers
- 196 people
- Sponsor
- AstraZeneca
Potassium Imbalance, Cardiac Arrhythmia
The Effect of Potassium Lowering Drugs on Cardiac Electrical Stability in Hemodialysis Patients (ART Study)
This study is a multicenter, prospective and randomized controlled study. The experiment includes a 1-week screening period (1 week before dialysis) and a 7-week treatment period (1-4 weeks of dose drip period and 5-7 weeks of…
- Conditions
- Potassium Imbalance, Cardiac Arrhythmia, Dialysis; Complications
- Trial name
- NCT06242041
- Testing
- sodium zirconium cyclic silicate
- Where
- China
- Volunteers
- 61 people
- Sponsor
- Peking University First Hospital
Hypertension, Potassium Imbalance
Occurrence of Dyskalemia With Treatment for Hypertension
Hypertension is a major public health issue associated with significant morbidities and mortality. Fixed-dose combination (FDC) pills, combining 2 or more classes of antihypertensive medications have considerable appeal because…
- Trial name
- OK (NCT05155436)
- Testing
- Fixed Dose Combination pill of Telmisartan 40mg and Amlodipine 5 mg
- Where
- Bangladesh
- Volunteers
- 1,090 people, healthy volunteers welcome
- Sponsor
- National Heart Foundation of Bangladesh
Hyperkalemia
Safety & Efficacy of Zirconium Silicate Dosed for 28 Days in Hyperkalemia.
It is hypothesized that ZS is more effective than placebo control (alternative hypothesis) in maintaining mean double-blind randomized maintenance phase (DBRMP) Day 8-29 serum potassium levels (3.5 - 5.0 mmol/l, inclusive) among…
- Trial name
- NCT02088073
- Testing
- Sodium zirconium cyclosilicate
- Where
- 46 sites in United States, Australia and 1 more
- Volunteers
- 258 people
- Sponsor
- ZS Pharma, Inc.
Hyperkalemia
A Study to Detect Hyperkalemia Using Smartphone-enabled Electrocardiogram (EKG)
The purpose of this study is to validate the real-world performance of a previously developed Artificial Intelligence - Electrocardiogram (AI-ECG) algorithm for identification of hyperkalemia with a six-lead mobile-enhanced…
- Trial name
- REACT (NCT05441852)
- Where
- United States
- Volunteers
- 1,151 people
- Sponsor
- Mayo Clinic
Chronic Kidney Diseases, Hyperkalemia
Use of Patiromer to Transition Chronic Kidney Disease Patients With Hyperkalemia to a Plant-rich Diet.
The purpose of this proof-of-concept controlled-feeding study is to determine whether patiromer (Veltassa®, Relypsa, Inc., Redwood City, CA) can be used to maintain normal serum potassium concentrations in chronic kidney disease…
- Trial name
- NCT03183778
- Testing
- Patiromer, Research Diet Menu
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- NYU Langone Health
Hyperkalemia
Open-label Safety & Efficacy of ZS (Sodium Zirconium Cyclosilicate)10g qd to Extend Study ZS-004 in Hyperkalemia.
Subjects who completed the Double-blind Randomized Maintenance Phase (DBRMP) Study Day 29 visit in ZS-004 (NCT 02088073) and have an i-STAT potassium value that is 3.5 to 6.2 mmol/l inclusive or who discontinued during ZS-004 due…
- Trial name
- NCT02107092
- Testing
- Sodium Zirconium Cyclosilicate
- Where
- 49 sites in United States, Australia and 1 more
- Volunteers
- 123 people
- Sponsor
- ZS Pharma, Inc.
Hypertension
Increasing Potassium Intake in Hypertensive Individuals
This study evaluates the safety of increasing dietary potassium intake in a hypertensive population that may be at risk for hyperkalemia.
- Trial name
- NCT02759367
- Testing
- High potassium diet
- Volunteers
- 20 people
- Sponsor
- Samuel Lunenfeld Research Institute, Mount Sinai Hospital
Hyperkalemia, Heart Failure
Evaluation of Patiromer in Heart Failure Patients
The purpose of this study was to assess the effects of patiromer on serum potassium participants with heart failure. This study also assessed the safety and tolerability of patiromer in participants with heart failure.
- Trial name
- PEARL-HF (NCT00868439)
- Testing
- patiromer
- Where
- 33 sites in United States, Czechia and 5 more
- Volunteers
- 120 people
- Sponsor
- Relypsa, Inc.
Hyperkalaemia
A National, Multicenter, Prospective, Observational Study to Assess Patient Characteristics, Treatment Algorithms and Disease Management of Hyperkalaemia Patients With Chronic Kidney Disease or Under Dialysis or With Heart Failure, Treated With Sodium Zirconium Cyclosilicate in Greece
This is a multicenter, observational, prospective, national study which includes patients with chronic kidney disease (CKD) under dialysis or not, or with heart failure (HF), treated with sodium zirconium cyclosilicate (SZC) as…
- Trial name
- SHIELD (NCT06185660)
- Testing
- sodium zirconium cyclosilicate (SZC)
- Where
- 10 sites in Greece
- Volunteers
- 125 people
- Sponsor
- AstraZeneca
Hyperkalemia
The Safety and Tolerability of WS016 in Healthy Chinese Volunteers
This clinic trial evaluates the safety and tolerability of single- and multiple- ascending doses of WS016 in healthy adult participants. There will be about 64 participants,48 active and 16 placebo.
- Trial name
- NCT06281470
- Testing
- WS016 Single Dose(6g), WS016 Single Dose(12g), WS016 Single Dose(24g)
- Where
- China
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Waterstone Pharmaceutical (Wuhan) Co., LTD.
Hyperkalemia
Patiromer With or Without Food for the Treatment of Hyperkalemia
The purpose of this study is to evaluate the efficacy and safety of patiromer administered once daily (QD) when given with food compared to without food (experimental treatment group) for the treatment of hyperkalemia (high…
- Trial name
- TOURMALINE (NCT02694744)
- Testing
- patiromer
- Where
- 29 sites in United States
- Volunteers
- 114 people
- Sponsor
- Relypsa, Inc.
Hyperkalemia, Kidney Transplant
Pharmacokinetic Study of Tacrolimus and Mycophenolate Mofetil in Kidney Transplant Recipients With Hyperkalemia Receiving Patiromer
Hyperkalemia (high potassium in blood) is a common condition found in kidney transplant patients. Risk factors include poor kidney function and exposure to various drugs.
- Trial name
- NCT03229265
- Testing
- Patiromer
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- The Rogosin Institute
Hyperkalaemia, Metabolic Acidosis
Study of the Effect of SZC on Serum Potassium and Serum Bicarbonate in Patients With Hyperkalemia and Metabolic Acidosis Associated With Chronic Kidney Disease
The main objective of this study is to evaluate the efficacy of SZC as compared to placebo in maintaining normal sK+ in patients with hyperkalemia and metabolic acidosis associated with CKD
- Conditions
- Hyperkalaemia, Metabolic Acidosis, Chronic Kidney Disease
- Trial name
- NEUTRALIZE (NCT04727528)
- Testing
- Sodium zirconium cyclosilicate
- Where
- 30 sites in United States, Puerto Rico
- Volunteers
- 39 people
- Sponsor
- AstraZeneca
Chronic Kidney Disease (CKD), Hyperkalemia (HK)
A Two-Part, Single-Blind, Phase 3 Study Evaluating the Efficacy and Safety of Patiromer for the Treatment of Hyperkalemia (OPAL)
The purpose of this study was to evaluate the efficacy and safety of patiromer (investigational drug) in the treatment of hyperkalemia (high serum potassium).
- Trial name
- OPAL (NCT01810939)
- Testing
- Patiromer
- Where
- 58 sites in United States, Croatia and 8 more
- Volunteers
- 243 people
- Sponsor
- Relypsa, Inc.
Chronic Kidney Diseases
Effects of a Whole-food, Plant-based Nutrition Program on BP and Potassium in Subjects With CKD
The purpose of this study is to determine if an educational program emphasizing a whole food plant based diet favorably impacts blood pressure while not significantly increasing blood potassium levels, by comparing a group of…
- Trial name
- NCT06343129
- Testing
- Dietary education program
- Where
- 2 sites in United States
- Volunteers
- 43 people
- Sponsor
- University of Rochester
Hyperkalemia
Early Protein Supplementation on Prevention of Hyperkalemia
Evaluate if early protein supplementation decreases the incidence of hyperkalemia in Extremely Low Birth Weight Infants (babies less than 1,000 grams birth weight).
- Trial name
- NCT00290160
- Testing
- Protein supplementation
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Hyperkalemia
A Safety and Pharmacodynamic Study of Healthy Chinese Subjects Administered Sodium Zirconium Cyclosilicate (ZS)
This is a single center, inpatient, open label pharmacodynamic study to determine the effect of 5 g and 10 g doses of Sodium Zirconium Cyclosilicate (ZS) administered once daily (qd) for 4 days on potassium and sodium excretion…
- Trial name
- NCT03283267
- Testing
- Sodium Zirconium Cyclosilicate (ZS)
- Where
- Hong Kong
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Hyperkalemia
An Observational Prospective Cohort Study for Long-term Management of Hyperkalemia in Patients With Chronic Kidney Disease or Heart Failure
This prospective observational research will be conducted to assess the burden of hyperkalemia including treatment and disease burden of patients in a long-term continuous care from various aspects including adherence to the…
- Trial name
- HK registry (NCT05297409)
- Where
- 32 sites in Japan
- Volunteers
- 352 people
- Sponsor
- AstraZeneca